STOCK TITAN

TAK Form 144: 28.5k ADS Insider Sale Planned for July 2025

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

The Form 144 filing indicates that an unidentified holder intends to sell 28,552 American Depositary Shares (ADSs) of Takeda Pharmaceutical Company Ltd. (NYSE: TAK) through Interactive Brokers on or about 9 July 2025. The planned sale represents an aggregate market value of US$440,271.84, implying an approximate price of US$15.42 per ADS. The shares derive from restricted stock unit (RSU) awards that vested on 1 July 2025. No other securities have been sold by the filer in the past three months, and the total shares outstanding for Takeda are disclosed as 123,490,548 ADSs, making the proposed sale equal to roughly 0.02 % of the class. No adverse information about Takeda’s operations is asserted, and the filer affirms compliance with Rule 144 and Rule 10b5-1 representations.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Small insider sale (28.5k ADS) worth ~US$440k; immaterial versus Takeda’s float—neutral signal.

The filing is a routine Form 144 notification. The proposed disposition amounts to ~0.02 % of Takeda’s outstanding ADSs and is valued at less than half a million dollars, negligible against the company’s multi-billion-dollar market capitalization. Because the shares stem from recently vested RSUs, the transaction likely serves liquidity or tax-planning purposes rather than signaling a view on fundamentals. No pattern of recent sales is noted, and the filer certifies absence of undisclosed negative information. Overall, I view the filing as not impactful for valuation or sentiment.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

How many Takeda (TAK) ADSs are being sold under this Form 144 notice?

The filer plans to sell 28,552 ADSs.

What is the aggregate market value of the proposed Takeda ADS sale?

The sale is valued at approximately US$440,271.84.

When is the approximate sale date listed in the Form 144 for Takeda?

The shares are expected to be sold on or about 9 July 2025.

What percentage of Takeda’s outstanding ADSs does the proposed sale represent?

Roughly 0.02 % of the 123,490,548 ADSs outstanding.

Where will the Takeda ADSs be sold according to the filing?

Through Interactive Brokers LLC on the NYSE.
Takeda Pharm

NYSE:TAK

View TAK Stock Overview

TAK Rankings

TAK Latest News

TAK Latest SEC Filings

TAK Stock Data

57.06B
3.16B
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Japan
Tokyo